You are right on the money, many things are not in the company's hands, they do their part, but others must do theirs. I believe that the FDA is particularly slow in documenting the use of historical data though they covered it in depth in Annuls of Oncology. The UK and I believe the rest of Europe will be far faster adopting DCVAX-L than our FDA. Canada may follow the UK lead, that is hard to say.
If the company announced that the UK has accepted their application and they anticipated actions by them in 4 months or less the importance of the Journal would be greatly diminished, but it's issuance would still be good news.
Gary